Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581207 | 0.78 | CYP2A6 (0.52) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29196077 | 0.78 | CA2 (0.53) | CYP2A6MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1849150 | 0.78 | CYP2A6 (0.52) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13195264 | 0.78 | CYP2A6 (0.52) | CYP2A6ALDH1A1CHRNA7HTR3ACYP1A2 | |
| SCHEMBL12095234 | 0.78 | CYP2A6 (0.52) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16693154 | 0.77 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3614712 | 0.77 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3614713 | 0.77 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9526357 | 0.74 | CYP2A6 (0.56) | CYP2A6ALDH1A1TDP1CYP1A2 | |
| SCHEMBL16693056 | 0.74 | CYP2A6 (0.47) | CYP2A6ALDH1A1CHRNA7HTR3ASLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2947085-B1 | OXAZOLIDONE COMPOUNDS, METHOD FOR PREPARING AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2017-09-13 | — | — | EP | disclosed |
| EP-2947085-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014110971-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | 中国科学院上海药物研究所 (CN) | 2014-07-24 | — | — | WO | disclosed |
| US-8778932-B2 | Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. | 2014-06-05 | — | — | US | disclosed |
| EP-2694491-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2497774-B1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB (FR) | 2013-10-16 | — | — | EP | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2012138776-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| CN-102675341-A | Dihydro-triazole and benzo two nitrogen heterocyclic ketones compound, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB | 2012-09-19 | — | — | CN | disclosed |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EGIS GYOGYSZERGYAR NYRT (HU) | 2012-09-13 | — | — | US | disclosed |
| WO-2012120206-A1 | NOVEL DIHYDRO-OXAZOLOBENZODIAZEPINONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2012-09-13 | — | — | WO | disclosed |
| EP-2497774-A1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | Les Laboratoires Servier (FR) | 2012-09-12 | — | — | EP | disclosed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | JAK2, JAK3, JAK1 | CYP2A6 4531/4885HDAC3 634/4885HDAC4 1632/4885 |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, PDK2 | CYP2A6 552/4885HDAC3 2173/4885HDAC4 2309/4885 |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GRIN2C, GRIN2B, GRIN2A | CYP2A6 179/4885HDAC3 397/4885HDAC4 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.